Patch test with sorbitan sesquioleate in Italian consecutive patients: A 1‐year multicenter SIDAPA study

Stingeni, Luca; Tramontana, Marta; Bianchi, Leonardo; Foti, Caterina; Romita, Paolo; Patruno, Cataldo; Cristaudo, Antonio; Gallo, Rosella; Corazza, Monica; Schena, Donatella; Pigatto, Paolo D.; Milanesi, Nicola; Nettis, Eustachio; Guarneri, Fabrizio; Hansel, Katharina

doi:10.1111/cod.13359

Cited by 12 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data suggest that positive patch test reactions to MP and to FM1 frequently do not coincide, and many relevant allergies would be missed if MP was excluded from baseline patch test series: in our population, 2.6% were positive only to MP and among patients with clinically relevant allergy to MP (n = 342), 233 (68.1%) were negative to FM1. Our data also show that coreactivity to MP and FM1 can be explained by sensitization to SSO only in few cases, as already suggested in the literature 1,4 …”

Section: Discussionsupporting

confidence: 90%

“…Our data also show that coreactivity to MP and FM1 can be explained by sensitization to SSO only in few cases, as already suggested in the literature. 1 , 4 …”

Section: Discussionmentioning

confidence: 99%

“…Our data also show that coreactivity to MP and FM1 can be explained by sensitization to SSO only in few cases, as already suggested in the literature. 1,4 Crude MP cannot be used in perfumes and cosmetics, whereas some extracts and distillates are allowed with restrictions 1 : this might explain the higher percentage of women, main consumers of such products, 5,6 among patients allergic to FM1 only.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Myroxylon pereirae (balsam of Peru): Still worth testing?

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Because Myroxylon pereirae (MP), or balsam of Peru, is nowadays almost not used “as such,” and fragrance mix 1 (FM1) apparently is more sensitive in detecting fragrance allergy, the usefulness of testing MP in baseline series was recently questioned. Objectives Identification of the number of clinically relevant patch test reactions to MP not detected by FM1. Methods Retrospective analysis of 12 030 patients patch tested with MP and FM1 for contact dermatitis between January 2018 and December 2019 in 13 Italian dermatology clinics. Results Four hundred thirty‐nine patients (3.6%) had a positive patch test reaction to MP; 437 (3.6%) had a positive patch test reaction to FM1. Positive reactions to both MP and FM1 were observed in 119 subjects (1.0%), 310 (2.6%) reacted to MP only, 304 (2.5%) to FM1 only, 5 to MP and sorbitan sesquioleate (SSO), 9 to FM1 and SSO, and 5 to MP, FM1, and SSO. Single sensitizations were clinically relevant in 75.2% of cases for MP (62.9% current, 12.3% past) and 76.3% for FM1 (70.1% current, 6.2% past). Conclusions Based on our results, MP appears to be still worth testing along with FM1 in baseline series, because it allows detection of a remarkable number of fragrance allergies, often relevant, which would be otherwise missed.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Our data also show that coreactivity to MP and FM1 can be explained by sensitization to SSO only in few cases, as already suggested in the literature. 1 , 4 …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Myroxylon pereirae (balsam of Peru): Still worth testing?

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…This rate was higher than previously reported rates for Denmark (0.2%) and Italy (0.5%) and lower than rates for Germany (0.8%), Belgium (1.5%) and the Netherlands (2.7%). 10,[13][14][15] In Germany and Belgium, SSO was added to the baseline patch test series in 2015 and 2018, respectively. 10 Studies from the USA reported higher positivity rates of 3.9% and 10.7%, which was mainly explained by the more widespread use of SSO or possible crossreactants in topical corticosteroid (TCS) products in the USA, 4,6 with SSO being second most common potential allergen present in TCS creams after propylene glycol.…”

Section: Discussionmentioning

confidence: 99%

“…1,[5][6][7] Similar to our findings, European studies have reported that SSO sensitization was mainly induced by cosmetic/skin care products and by topical medicaments other than corticosteroids. 13,14 By contrast, topical corticosteroids were regarded as a more or equally frequent cause of SSO contact sensitization in the USA. [4][5][6] It was stated that up to 75% of patients with a positive patch test reaction to SSO and/or SMO were using topical corticosteroids containing SSO or chemically related substances, and 78% of them improved following switching to a topical corticosteroid without SSO or possible crossreactants.…”

Section: Discussionmentioning

confidence: 99%

Sorbitan sesquioleate: a rare contact allergen that is also an important indicator of allergic contact dermatitis from crossreacting compounds as well as for false‐positive fragrance allergy

Özkaya

Pehlivan

Kobaner

2022

Clin Experimental Derm

View full text Add to dashboard Cite

Summary Background Controversy exists about the addition of sorbitan sesquioleate (SSO) to the European baseline series for concomitant patch testing, particularly with fragrance mix (FM) I and Myroxylone pereirae (MP), which both contain SSO as an emulsifier. Aim To investigate SSO contact sensitization and concomitant positive patch test reactions to FM I or MP in Turkey. Methods This was a retrospective analysis of 840 patients consecutively patch tested with SSO 20% petrolatum between 1996 and 2020. Results The prevalence of SSO sensitization was 0.6% (5 of 840). In four of the five patients, clinical relevance could be established from SSO crossreactants, mainly in moisturizers and topical pharmaceuticals other than corticosteroids. Positive patch test reactions with unknown clinical relevance were observed to FM I or MP (both containing 5% SSO) in 71.4% of patients with a positive/questionable positive reaction to SSO (P < 0.001) and to other patch test allergens containing 1–5% SSO. Conclusions SSO was a very good indicator for positive patch test reaction with unknown clinical relevance to fragrances and other allergens containing 1–5% SSO. We suggest that SSO should be tested as a negative control with any commercially available patch test allergen containing SSO at any concentration. Moreover, clinicians should be alert for SSO synonyms and for other sorbitan derivatives in product labels, as SSO itself might not be the culprit but an indicator for crossreacting allergens.

show abstract